Trial Profile
A phase II study of mocetinostat in selected patients with solid tumours
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Aug 2015
Price :
$35
*
At a glance
- Drugs Mocetinostat (Primary)
- Indications Bladder cancer; Solid tumours
- Focus Therapeutic Use
- 05 Aug 2015 Status changed from planning to recruiting, as per Mirati Therapeutics media release.
- 09 Jul 2014 New trial record